Education
About Us
Working with TipRanks
Follow Us
Prothena (PRTA)
NASDAQ:PRTA
PRTA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.32 - $22.41
Previous CloseN/A
Volume58.73K
Average Volume (3M)1.07M
Market Cap
$439.25M
Enterprise Value-$34.92M
Total Cash (Recent Filing)$371.44M
Total Debt (Recent Filing)$9.78M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Oct 30, 2025EPS Estimate
-0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.34
Shares Outstanding53,829,983
10 Day Avg. Volume836,036
30 Day Avg. Volume1,067,878
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.08
Enterprise Value/Revenue-3.38
Enterprise Value/Gross Profit-3.70
Enterprise Value/Ebitda0.14
Forecast
1Y Price Target
$12.00Price Target Upside47.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentThe company plans to share the much-awaited data from the PRX012 MAD study, which if encouraging can be a catalyst for either a strategic partnership or an acquisition given the strong Alzheimer’s disease focused pipeline.
Strategic PartnershipsMAD data showing robust plaque reduction while maintaining lower ARIA rate can be encouraging for strategic partnership.
Therapeutic PotentialThe company’s decision to evaluate 200 mg and 400 mg doses using a once-monthly regimen underscores confidence in PRX012’s potential and reflects a patient-friendly dosing model, particularly well-suited for subcutaneous administration in Alzheimer’s patients.
Bears Say
Clinical Trial FailureBirtamimab did not show survival benefit in severe ALA.
Cost ReductionsThe company said it will now work on reducing operating expenses that will include and won’t be limited to a substantial workforce reduction.
Financial StabilityThere are concerns about further cash burn in a difficult capital markets environment, impacting the company's financial stability.
Prothena News
PRTA FAQ
What was Prothena’s price range in the past 12 months?
Prothena lowest stock price was $4.32 and its highest was $22.41 in the past 12 months.
What is Prothena’s market cap?
Prothena’s market cap is $439.25M.
When is Prothena’s upcoming earnings report date?
Prothena’s upcoming earnings report date is Oct 30, 2025 which is in 42 days.
How were Prothena’s earnings last quarter?
Prothena released its earnings results on Aug 04, 2025. The company reported -$2.34 earnings per share for the quarter, missing the consensus estimate of -$1.254 by -$1.086.
Is Prothena overvalued?
According to Wall Street analysts Prothena’s price is currently Undervalued.
Does Prothena pay dividends?
Prothena does not currently pay dividends.
What is Prothena’s EPS estimate?
Prothena’s EPS estimate is -0.69.
How many shares outstanding does Prothena have?
Prothena has 53,829,983 shares outstanding.
What happened to Prothena’s price movement after its last earnings report?
Prothena reported an EPS of -$2.34 in its last earnings report, missing expectations of -$1.254. Following the earnings report the stock price went up 1.297%.
Which hedge fund is a major shareholder of Prothena?
Currently, no hedge funds are holding shares in PRTA
Prothena Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (47.06% Upside)
$12.00 (47.06% Upside)
Hedge Fund Trend
Increased
By 34.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.5%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.72%
12-Months-Change
Fundamentals
Return on Equity
-66.85%
Trailing 12-Months
Asset Growth
-38.18%
Trailing 12-Months
Company Description
Prothena
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
PRTA Stock 12 Month Forecast
Average Price Target
$12.00
▲(47.06% Upside)
Technical Analysis
Rocket Pharmaceuticals
―
KalVista Pharmaceuticals
―
Replimune Group
―
Immunome
―
Bicara Therapeutics Inc.
―
Ownership Overview
24.47% Insiders
30.56% Mutual Funds
22.94% Other Institutional Investors
15.74% Public Companies and
Individual Investors